Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins.
Capsular polysaccharides (CPs), present on the surface of most pathogenic bacteria, have been recognised as virulence factors. Antibodies specific to these polysaccharides can mediate the killing of these bacteria by phagocytes in the presence of complement. The conjugation of polysaccharides to carrier proteins enhances their immunogenicity and renders the immune response T-cell dependent. The currently licensed capsular polysaccharide vaccines and polysaccharide-protein conjugate vaccines under development for the prevention of bacterial infections will be discussed in this review. Use of these vaccines for active vaccination and for the vaccination of healthy plasma donors to produce hyperimmune iv. immunoglobulins for the passive immunisation of appropriate patient populations is also discussed.
Walter Karakawa Microbial Pathogenesis Laboratory, Nabi, 12280 Wilkins Avenue, Rockville, MD 20852, USA.
R K
RK
Sood
A
A
Fattom